Summary
• GT Biopharma, Inc. (GTBP) shares rose 3.6% in pre-market trading to $0.6793 after the release of its third-quarter earnings report on November 14.
• The company reported a loss of $0.83 per share, missing expectations of a $0.38 loss, while highlighting ongoing enrollment in a Phase 1 trial for its GTB-3650 TriKE treatment.
• Despite the positive market reaction, GTBP’s yearly stock performance has declined by 79.7%, with analysts maintaining a “Buy” rating based on its developmental prospects.
GT Biopharma, Inc. (GTBP) is experiencing a pre-market uptick, trading at $0.6793—an increase of 3.6% from its last close of $0.6555. This movement reflects a positive investor reaction following the company’s third-quarter financial results unveiled on November 14.
Earnings Beat and Corporate Update
In its latest earnings report, GT Biopharma posted an actual loss of $0.83 per share, which significantly missed analysts’ expectations of a loss of $0.38, resulting in a surprise of 118%. Despite this earnings miss, the company provided a corporate update highlighting the ongoing Phase 1 trial of its GTB-3650 TriKE for relapsed or refractory CD33 expressing hematologic malignancies, which continues to enroll patients actively. The next update on this trial is anticipated in Q1 2026.
Regulatory Filings and Corporate Developments
Alongside the financial results, the company filed an 8-K on the same day, detailing these results and updates. The filing can be accessed through the SEC’s website for shareholders seeking further information on corporate developments and financial metrics.
Market and Technical Picture
Despite the recent rally, GTBP’s yearly performance reflects a 79.7% decline, while quarter-over-quarter performance shows a drop of 64.4%. The stock is currently trading below its 20-day and 50-day simple moving averages by approximately 2% and 8% respectively, while the 200-day average shows a notable deviation of around 64.6%. Notably, the average volume over the past 10 days stands at 2,167,535 shares, significantly higher than the 3-month average of 1,804,702 shares, indicating heightened trading interest.
Analyst Sentiment
Analysts have maintained a “Buy” rating on GTBP, suggesting that despite the recent volatility and earnings miss, there is potential for upside based on its developmental pipeline and strategic initiatives.
With GT Biopharma’s stock reacting positively in pre-market trading, investors appear to be cautiously optimistic about its pipeline developments, even as the company navigates its current financial challenges.